To suggest therapeutic molecular targets and candidate drugs for ETV4-fusion-positive prostate cancer, gene–drug network analysis was performed using 86 genes involved in cancer-specific pathways of ETV4-fusion-positive prostate cancer. This evidence concerns the gene ETV4 and prostate cancer.